RSS   Newsletter   Contact   Advertise with us

Boston Scientific to buy Xlumena for $62.5 million plus milestones

Share on Twitter Share on LinkedIn
Staff writer ▼ | April 3, 2015
Boston Scientific Corporation has signed a definitive agreement to acquire Xlumena, a medical device company.
Boston Scientific
Acquisition   Minimally-invasive approaches
The Xlumena portfolio includes the Axios and HOT Axios Stent and Delivery Systems. The Axios Stent and Delivery System has received U.S. Food and Drug Administration (FDA) clearance and is the world's first stent designed for endoscopic ultrasound-guided transluminal drainage of symptomatic pancreatic pseudocysts.

The next-generation Hot Axios Stent and Delivery System incorporates cautery into the delivery of the Axios stent. Both systems have CE Mark for facilitating transgastric or transduodenal endoscopic drainage of pancreatic pseudocysts or the biliary tract. These products are currently sold in select countries in Europe.

"We believe the acquisition of Xlumena and their minimally-invasive products combined with the Boston Scientific broad product portfolio demonstrates our commitment to advancing the field of interventional EUS therapeutics," said David Pierce, senior vice president and president, Endoscopy, Boston Scientific.

The Axios technology platform broadens the Boston Scientific portfolio of minimally-invasive approaches to treat pancreatic pseudocysts which may be caused by pancreatitis (acute or chronic inflammation of the pancreas), pancreatic ductal obstruction or trauma. The acquisition accelerates the Boston Scientific commitment to lead the EUS segment by coupling the Expect family of Fine Needle Aspiration (FNA) needles with the leader in therapeutic EUS.

"We are proud to see our technology evolve in conjunction with Boston Scientific's portfolio and provide patients a holistic and minimally invasive solution," said Greg Patterson, president and chief executive officer of Xlumena.

The agreement calls for an upfront payment of $62.5 million, an additional payment of $12.5 million upon FDA clearance of the HOT Axios product, and further sales-based milestones based on sales achieved through 2018.

Boston Scientific currently expects the net impact of this transaction on adjusted earnings per share to be immaterial for years 2015 and 2016 and break-even to accretive thereafter, and more dilutive on a GAAP basis as a result of acquisition-related net charges and amortization.


 

MORE INSIDE POST